热门资讯> 正文
Senti Biosciences将分拆其基因电路管道
2026-07-15 19:59
- Senti Biosciences Holdings (SNTI) on Wednesday said privately held NewCo controlled by affiliates of top investor Celadon will acquire its gene-circuit pipeline, including SENTI-202.
- Equity holders are to receive a contingent value right offering up to $60M in milestone payments tied to SENTI-202 development, FDA approval, and sales.
- Senti to focus on its Regulator Dial technology platform and seek additional financing after the transaction closes.
More on Senti Biosciences
- Seeking Alpha’s Quant Rating on Senti Biosciences
- Historical earnings data for Senti Biosciences
- Financial information for Senti Biosciences
推荐文章
财报前瞻 | 股价冲高四成后急降温！小米Q2净利料降40%，高盛喊出“盈利谷底”已出现！
算力市场格局分化：CoreWeave、Nebius冲刺短期高毛利，AWS深耕长约
PayPal洽谈出售：Stripe与私募巨头Advent联手出价，谈判报价已超530亿美元
英伟达正洽谈向软银支持的SB Energy最高投资30亿美元 服务OpenAI巨型数据中心建设
美国欲在经济上孤立伊朗 贝森特手里有哪些牌可打
伯克希尔Q2增持谷歌170亿美元
港股周报 | 恒生科指官宣重大改革！联想集团周内飙涨19%，腾讯单季砸下528亿元豪赌AI
老虎环球Q2押注AI“二线选手”：新进Cerebras和AMD，增持英特尔，十大重仓股全线减持
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
